SUMO on the road to neurodegeneration

被引:148
作者
Dorval, Veronique [1 ]
Fraser, Paul E. [1 ]
机构
[1] Univ Toronto, Dept Med Biophys, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 2007年 / 1773卷 / 06期
基金
加拿大健康研究院;
关键词
SUMO; neurodegenerative diseases; proteasome; ubiquitin; neuronal inclusions; INTRANUCLEAR INCLUSION DISEASE; UBIQUITIN-PROTEASOME SYSTEM; MODIFIER SUMO; PROTEIN SUMOYLATION; HUNTINGTONS-DISEASE; ANDROGEN RECEPTOR; COVALENT MODIFICATION; CONJUGATION PATHWAYS; NUCLEAR-LOCALIZATION; ALZHEIMER-DISEASE;
D O I
10.1016/j.bbamcr.2007.03.017
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sumoylation is a post-translational modification by which small ubiquitin-like modifiers (SUMO) are covalently conjugated to target proteins. This reversible pathway provides a rapid and efficient way to modulate the subcellular localization, activity and stability of a wide variety of substrates. Similar to its well-known cousin ubiquitin, SUMO co-localize with the neuronal inclusions associated with several neurodegenerative diseases, including multiple system atrophy, Huntington's disease and other related polyglutarnine disorders. The identification of huntingtin, ataxin-1, tau and alpha-synuclein as SUMO substrates further supports the involvement of sumoylation in the pathogenesis of this family of neurological diseases. In addition to direct. targeting of these constituent proteins, sumoylation also impacts other disease pathways such as oxidative stress, protein aggregation and proteasome-mediated degradation. This review highlights the recent advances in understanding the contributions of SUMO to neurodegeneration and the underlying pathogenic mechanisms of these diseases. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:694 / 706
页数:13
相关论文
共 115 条
[1]   Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death [J].
Arrasate, M ;
Mitra, S ;
Schweitzer, ES ;
Segal, MR ;
Finkbeiner, S .
NATURE, 2004, 431 (7010) :805-810
[2]   Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling [J].
Bailey, D ;
O'Hare, P .
BIOCHEMICAL JOURNAL, 2005, 392 :271-281
[3]   Caspase-8 sumoylation is associated with nuclear localization [J].
Besnault-Mascard, L ;
Leprince, C ;
Auffredou, MT ;
Meunier, B ;
Bourgeade, MF ;
Camonis, J ;
Lorenzo, HK ;
Vazquez, A .
ONCOGENE, 2005, 24 (20) :3268-3273
[4]   A mechanism for inhibiting the SUMO pathway [J].
Boggio, R ;
Colombo, R ;
Hay, RT ;
Draetta, GF ;
Chiocca, S .
MOLECULAR CELL, 2004, 16 (04) :549-561
[5]   A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus [J].
Bohren, KM ;
Nadkarni, V ;
Song, JH ;
Gabbay, KH ;
Owerbach, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (26) :27233-27238
[6]   Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes [J].
Bossis, G ;
Melchior, F .
MOLECULAR CELL, 2006, 21 (03) :349-357
[7]   SUMO: regulating the regulator [J].
Bossis, Guillaume ;
Melchior, Frauke .
CELL DIVISION, 2006, 1 (1)
[8]   Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation [J].
Bowman, AB ;
Yoo, SY ;
Dantuma, NP ;
Zoghbi, HY .
HUMAN MOLECULAR GENETICS, 2005, 14 (05) :679-691
[9]   Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila [J].
Chan, HYE ;
Warrick, JM ;
Andriola, I ;
Merry, D ;
Bonini, NM .
HUMAN MOLECULAR GENETICS, 2002, 11 (23) :2895-2904
[10]  
CHEN ZJ, 1990, J BIOL CHEM, V265, P21835